Erdafitinib Disease Interactions
There are 3 disease interactions with erdafitinib.
Erdafitinib (applies to erdafitinib) hyperphosphatemia
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Phosphate Imbalance
Increases in phosphate levels are a pharmacodynamic effect of erdafitinib. Hyperphosphatemia was reported as adverse reaction in 76% of patients after initiating treatment, with 32% requiring phosphate binders during treatment. Caution and monitoring of phosphate levels is advised in all patients, especially in those at risk or hyperphosphatemia. Follow the manufacturer's dose modification guidelines if required.
Erdafitinib (applies to erdafitinib) ocular disorders
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Retinal Disorder
Erdafitinib can cause ocular disorders, including central serous retinopathy/retinal pigment epithelial detachment (CSR/RPED) resulting in visual field defect. Perform monthly ophthalmological examinations during the first 4 months of treatment and every 3 months afterwards, and urgently at any time for visual symptoms. Ophthalmological examination should include assessment of visual acuity, slit lamp examination, fundoscopy, and optical coherence tomography. Caution and close monitoring is advised in patients with retinal disorders. Follow manufacturers dose modification guidelines in patients at risk or with ocular adverse reactions.
Erdafitinib (applies to erdafitinib) severe hepatic/renal
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease
The pharmacokinetics of erdafitinib in patients with severe renal impairment, renal impairment requiring dialysis, moderate or severe hepatic impairment is unknown. Caution is advised if used in these patients.
Switch to professional interaction data
Erdafitinib drug interactions
There are 242 drug interactions with erdafitinib.
More about erdafitinib
- erdafitinib consumer information
- Check interactions
- Compare alternatives
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Durvalumab
Durvalumab (Imfinzi) is an immunotherapy used to treat lung cancer (NSCLC, SCLC) and other cancers ...
Doxorubicin
Doxorubicin systemic is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder ...
Nivolumab
Nivolumab (brand name Opdivo) is an immunotherapy treatment that treats many cancers, such as ...
Cisplatin
Cisplatin systemic is used for anal cancer, bladder cancer, blood cell transplantation, bone marrow ...
Pembrolizumab
Pembrolizumab (Keytruda) is a monoclonal antibody cancer medicine used to treat
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.